ForPatients
by Roche

Amyotrophic Lateral Sclerosis

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03237741 2017-000299-27 GP39778

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential. The first part of the study will compare the bioavailability of a prototype capsule of GDC-0134 relative to an existing GDC-0134 reference capsule (Periods 1 and 2). The second part of the study will assess the effect of GDC-0134-in-applesauce preparation under fasting conditions, the effect of low and high fat foods as well as the effect of elevated stomach pH via pre-treatment with rabeprazole, a proton pump inhibitor (PPI), under fasted and high-fat meal conditions (Periods 3 and 4).

Genentech, Inc. Sponsor	**Phase 1** Phase

NCT03237741 2017-000299-27 GP39778
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>= 30 Years & <= 65 Years	Accepts Healthy Volunteers